Drug
D0951 | genistein
| Toxicity | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| MEMBRANE POTENTIAL | 6.34±0.77 | human | qHTS-HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 10 | human | HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 33.67±19.54 | rat | hepatocytes | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 150.6 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | EC20 | 36 |
| RESPIRATION | 81.3 µM | 60 mins | mouse | liver mitochondria | Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Rotenone (2µM) was used as 100% baseline for complex I inhibition. | decrease | EC20 | 36 |
| RESPIRATION | ND | 60 mins | mouse | liver mitochondria | Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Oligomycin A (1µM) was used as 100% baseline for complex II inhibition. | Negative | EC20 | 36 |
| ELECTRON TRANSPORT CHAIN | 55 μM | rat | brain MF0F1-ATPase | decrease | IC50 | 140 | ||
| ELECTRON TRANSPORT CHAIN | 50 μM | rat | liver F1-ATPase | decrease | 10% inhibition | 141 | ||
| TRANSPORT OF CALCIUM | 37μM | mitochondrial Ca2+ uptake | increase | EC50 | 234 | |||
| SWELLING | > 200 µM | 30 mins | mouse | liver mitochondria | swelling assay: Absorbance at 545 nm using a fluorescence multi-well plate reader (CaCl2 (50 µM) was considered as the 100% baseline for the swelling ) | increase | EC20 | 36 |
| ELONGATION | mouse | neuron | Mitochondrial morphology and neurite area measurements | induce | 269 | |||
| Target | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| NADH:ubiquinone reductase | 81.3 µM | 60 mins | mouse | liver mitochondria | Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Rotenone (2µM) was used as 100% baseline for complex I inhibition. | inhibit | EC20 | 36 |
| Succinate dehydrogenase | ND | 60 mins | mouse | liver mitochondria | Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Oligomycin A (1µM) was used as 100% baseline for complex II inhibition. | Negative | EC20 | 36 |
| ATP synthase | 55 μM | rat | brain MF0F1-ATPase | inhibitor | IC50 | 140 | ||
| ATP synthase | 50 μM | rat | liver F1-ATPase | inhibitor | 10% inhibition | 141 | ||
| mCU (mitochondrial calcium uniporter) | 37μM | mitochondrial Ca2+ uptake | activate | EC50 | 234 | |||
| Cytochrome c | > 200 µM | 30 mins | mouse | liver mitochondria | Cytochrome c release was evaluated using ELISA kit ( 20 µg/ml Alamethicin was used as 100% baseline) | release | EC20 | 36 |
| Pictogram | Signal | Statements | Precautionary Statement Codes |
|---|---|---|---|
  |
Warning |
Aggregated GHS information provided by 213 companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. Reported as not meeting GHS hazard criteria by 6 of 213 companies. For more detailed information, please visit ECHA C&L website Of the 4 notification(s) provided by 207 of 213 companies with hazard statement code(s): H302 (97.58%): Harmful if swallowed [Warning Acute toxicity, oral] H315 (76.33%): Causes skin irritation [Warning Skin corrosion/irritation] H319 (76.33%): Causes serious eye irritation [Warning Serious eye damage/eye irritation] H335 (76.33%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure Respiratory tract irritation] H400 (74.4%): Very toxic to aquatic life [Warning Hazardous to the aquatic environment, acute hazard] H410 (74.4%): Very toxic to aquatic life with long lasting effects [Warning Hazardous to the aquatic environment, long-term hazard] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. |
P261, P264, P270, P271, P273, P280, P301+P312, P302+P352, P304+P340, P305+P351+P338, P312, P321, P330, P332+P313, P337+P313, P362, P391, P403+P233, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) |
| 1x7r | 2qa8 | 3-(4-hydroxyphenyl)-5,7-bis(oxidanyl)chromen-4-one |
| 3kgt | 3kgu | 4 inverted exclamation marka,5,7-Trihydroxyisoflavone |
| 4′,5,7-Trihydroxyisoflavone | 4',5, 7-Trihydroxyisoflavone | 4',5,7-TRIHYDROXYISOFLAVONE |
| 4',5,7-Trihydroxyisoflavone | 4',5,7-Trihydroxyisoflavone | 4',5,7-trihydroxy-Isoflavone |
| 4',7-Trihydroxyisoflavone | 4,5,7-Trihydroxy Iso-Flavone | 4,5,7-Trihydroxyisoflavone |
| 446-72-0 | 46G720 | 4H-1-Benzopyran-4-one, 5,7-dihydroxy-3-(4-hydroxyphenyl)- |
| 4H-1-Benzopyran-4-one,7-dihydroxy-3-(4-hydroxyphenyl)- | 5,7,4'-Trihydroxyisoflavone | 5,7-DIHYDROXY-3-(4-HYDROXYPHENYL)-4H-1-BENZOPYRAN-4-ONE |
| 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4-benzopyrone | 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one | 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one |
| 5,7-dihydroxy-3-(4-hydroxyphenyl)-1-benzopyran-4-one | 5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one | 5,7-dihydroxy-3-(4-hydroxyphenyl)chromen-4-one |
| 5-18-04-00594 (Beilstein Handbook Reference) | 690224-00-1 | A826657 |
| AB00052696_09 | AB00052696_12 | AB1004490 |
| AC-472 | ACT05962 | ACon1_001065 |
| AK161745 | AKOS001590147 | ALBB-015886 |
| AOB5073 | BBL010484 | BCP07581 |
| BDBM19459 | BIDD:ER0113 | BRD-K43797669-001-02-3 |
| BRD-K43797669-001-03-1 | BRD-K43797669-001-10-6 | BRN 0263823 |
| BSPBio_002375 | Bio 300 | Bio1_000445 |
| Bio1_000934 | Bio1_001423 | Bonistein |
| C.I. 75610 | C06563 | CAS-446-72-0 |
| CCG-38551 | CCRIS 7675 | CG-009 |
| CHEBI: 28088 | CHEBI:28088 | CHEMBL44 |
| CS-1534 | Certified Reference Material | DB01645 |
| DH2M523P0H | DSSTox_CID_2308 | DSSTox_GSID_22308 |
| DSSTox_RID_76542 | DTXSID5022308 | Differenol A |
| DivK1c_006401 | EINECS 207-174-9 | ENDOCRINE DISRUPTOR (GENISTEIN) (SEE ALSO GENISTEIN (446-72-0)) |
| EU-0100520 | F0001-2388 | FT-0603395 |
| FW-635I-2 | G 6649 | G-2535 |
| G0272 | GEN | GENISTEIN (ENDOCRINE DISRUPTER) |
| GENISTEOL; | GTPL2826 | Genestein |
| Genistein | Genistein (flavonoid) | Genistein 85% HPLC |
| Genistein [USAN] | Genistein, 8 | Genistein, 99%, synthetic |
| Genistein, Pharmaceutical Secondary Standard | Genistein, United States Pharmacopeia (USP) Reference Standard | Genistein, analytical standard |
| Genistein, from Glycine max (soybean), ~98% (HPLC) | Genistein, primary pharmaceutical reference standard | Genistein, synthetic, >=98% (HPLC), powder |
| Genistein,(S) | Genisteol | Genisterin |
| HMS2271K09 | HMS3261H21 | HMS3267K14 |
| HMS3412I13 | HMS3428M01 | HMS3649B22 |
| HMS3654D17 | HMS3676I13 | HMS3742I07 |
| HSDB 7475 | HY-14596 | ISOFLAVONE, 4',5,7-TRIHYDROXY- |
| Isoflavone,5,7-trihydroxy- | J10015 | K00046 |
| KBio1_001345 | KBio2_000800 | KBio2_002564 |
| KBio2_003368 | KBio2_005132 | KBio2_005936 |
| KBio2_007700 | KBio3_001595 | KBio3_003042 |
| KBioGR_002006 | KBioGR_002564 | KBioSS_000800 |
| KBioSS_002573 | KS-00000MH8 | KS-5128 |
| LMPK12050218 | LP00520 | LS-1266 |
| Lactoferrin-genistein | Lopac-G-6649 | Lopac0_000520 |
| MCULE-4857649752 | MEGxp0_000568 | MFCD00016952 |
| MLS000738127 | MolMap_000022 | N1861 |
| NCGC00015479-01 | NCGC00015479-02 | NCGC00015479-04 |
| NCGC00015479-05 | NCGC00015479-06 | NCGC00015479-07 |
| NCGC00015479-08 | NCGC00015479-09 | NCGC00015479-10 |
| NCGC00015479-11 | NCGC00015479-12 | NCGC00015479-13 |
| NCGC00015479-14 | NCGC00015479-15 | NCGC00015479-16 |
| NCGC00015479-17 | NCGC00015479-18 | NCGC00015479-19 |
| NCGC00015479-20 | NCGC00025005-01 | NCGC00025005-02 |
| NCGC00025005-03 | NCGC00025005-04 | NCGC00025005-05 |
| NCGC00025005-06 | NCGC00025005-07 | NCGC00169711-01 |
| NCGC00169711-02 | NCGC00254275-01 | NCGC00258979-01 |
| NCGC00261205-01 | NCI60_003369 | NPI 031L |
| NPI-031L | NSC 36586 | NSC-36586 |
| NSC36586 | Oprea1_224620 | Oprea1_437815 |
| PRUNETOL | PTI G4660 | PTI G4660 (Genistein) |
| PTI-G 4660 | PTI-G4660 | Prunetol |
| PubChem9852 | Q-100484 | Q415957 |
| S-7751 | SB17235 | SBB066115 |
| SC-04581 | SCHEMBL19166 | SIPI 807-1 |
| SIPI-807-1 | SIPI-9764-I | SMP1_000133 |
| SMR000112580 | SPBio_000636 | SPECTRUM210296 |
| SR-01000075498 | SR-01000075498-1 | SR-01000075498-10 |
| SR-01000075498-3 | SR-01000075498-6 | ST056352 |
| STK801619 | STO514 | SW203763-2 |
| SY050124 | Sophoricol | SpecPlus_000305 |
| Spectrum2_000638 | Spectrum3_000678 | Spectrum4_001543 |
| Spectrum5_000106 | Spectrum_000320 | TNP00151 |
| TZBJGXHYKVUXJN-UHFFFAOYSA-N | Tocris-1110 | Tox21_110161 |
| Tox21_110161_1 | Tox21_201428 | Tox21_300585 |
| Tox21_500520 | UNII-71B37NR06D component TZBJGXHYKVUXJN-UHFFFAOYSA-N | UNII-DH2M523P0H |
| UPCMLD-DP096 | UPCMLD-DP096:001 | US8552057, 2 |
| WHO 11073 | ZINC18825330 | cMAP_000086 |
| cid_5280961 | genistein | s1342 |